425 related articles for article (PubMed ID: 15522997)
1. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests.
Mari A; Gastaldelli A; Natali A; Ostergard T; Schmitz O; Ferrannini E
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E541-6. PubMed ID: 15522997
[TBL] [Abstract][Full Text] [Related]
2. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
3. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
4. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.
Rask E; Olsson T; Söderberg S; Holst Jj Jj; Tura A; Pacini G; Ahrén B
Metabolism; 2004 May; 53(5):624-31. PubMed ID: 15131768
[TBL] [Abstract][Full Text] [Related]
5. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
Kjems LL; Holst JJ; Vølund A; Madsbad S
Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
[TBL] [Abstract][Full Text] [Related]
6. Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects.
Mari A; Schmitz O; Gastaldelli A; Oestergaard T; Nyholm B; Ferrannini E
Am J Physiol Endocrinol Metab; 2002 Dec; 283(6):E1159-66. PubMed ID: 12388151
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
[TBL] [Abstract][Full Text] [Related]
8. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
[TBL] [Abstract][Full Text] [Related]
9. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
10. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.
Meier JJ; Gallwitz B; Askenas M; Vollmer K; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
Diabetologia; 2005 Sep; 48(9):1872-81. PubMed ID: 16010522
[TBL] [Abstract][Full Text] [Related]
11. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
[TBL] [Abstract][Full Text] [Related]
12. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
Greenbaum CJ; Prigeon RL; D'Alessio DA
Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
[TBL] [Abstract][Full Text] [Related]
13. Insulin sensitivity and secretion changes after gastric bypass in normotolerant and diabetic obese subjects.
Salinari S; Bertuzzi A; Guidone C; Previti E; Rubino F; Mingrone G
Ann Surg; 2013 Mar; 257(3):462-8. PubMed ID: 23388352
[TBL] [Abstract][Full Text] [Related]
14. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
Toft-Nielsen MB; Damholt MB; Madsbad S; Hilsted LM; Hughes TE; Michelsen BK; Holst JJ
J Clin Endocrinol Metab; 2001 Aug; 86(8):3717-23. PubMed ID: 11502801
[TBL] [Abstract][Full Text] [Related]
15. A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus.
Jones IR; Owens DR; Vora J; Luzio SD; Hayes TM
Diabetes Res Clin Pract; 1989 Nov; 7(4):263-9. PubMed ID: 2693029
[TBL] [Abstract][Full Text] [Related]
16. Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation.
Mari A; Tura A; Gastaldelli A; Ferrannini E
Diabetes; 2002 Feb; 51 Suppl 1():S221-6. PubMed ID: 11815483
[TBL] [Abstract][Full Text] [Related]
17. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance.
Ferrannini E; Gastaldelli A; Miyazaki Y; Matsuda M; Pettiti M; Natali A; Mari A; DeFronzo RA
Diabetologia; 2003 Sep; 46(9):1211-9. PubMed ID: 12879253
[TBL] [Abstract][Full Text] [Related]
18. Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits.
Gjesing AP; Ekstrøm CT; Eiberg H; Urhammer SA; Holst JJ; Pedersen O; Hansen T
Diabetologia; 2012 May; 55(5):1338-45. PubMed ID: 22349073
[TBL] [Abstract][Full Text] [Related]
19. Interaction of fat-stimulated gastric inhibitory polypeptide on pancreatic alpha and beta cell function.
Verdonk CA; Rizza RA; Nelson RL; Go VL; Gerich JE; Service FJ
J Clin Invest; 1980 May; 65(5):1119-25. PubMed ID: 6988457
[TBL] [Abstract][Full Text] [Related]
20. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.
Rask E; Olsson T; Söderberg S; Johnson O; Seckl J; Holst JJ; Ahrén B;
Diabetes Care; 2001 Sep; 24(9):1640-5. PubMed ID: 11522713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
